These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31456235)

  • 21. Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?
    Kotze PG; Danese S
    Curr Med Chem; 2019; 26(2):246-247. PubMed ID: 30907307
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
    Lyman GH
    J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
    [No Abstract]   [Full Text] [Related]  

  • 23. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars in inflammatory bowel disease.
    Moore GT
    Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
    [No Abstract]   [Full Text] [Related]  

  • 26. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.
    Felice C; Pugliese D; Armuzzi A
    Expert Opin Biol Ther; 2019 Oct; 19(10):967-969. PubMed ID: 30616459
    [No Abstract]   [Full Text] [Related]  

  • 27. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?
    Fiorino G; Fazio M; Danese S
    Expert Rev Clin Immunol; 2016; 12(4):361-3. PubMed ID: 26752540
    [No Abstract]   [Full Text] [Related]  

  • 28. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).
    Franchimont D; Ferrante M; Louis E; De Vos M; Dewit O; Van Hootegem P; Moreels T; Liefferinckx C; Bossuyt P; Baert F; Rahier JF; Vermeire S
    Acta Gastroenterol Belg; 2018; 81(1):49-53. PubMed ID: 29562378
    [No Abstract]   [Full Text] [Related]  

  • 29. Biosimilar medicines in inflammatory bowel disease.
    Moum B; Lundin KE
    Tidsskr Nor Laegeforen; 2014 Apr; 134(8):819-20. PubMed ID: 24780979
    [No Abstract]   [Full Text] [Related]  

  • 30. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
    Patel D; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars in IBD: from theory to practice.
    Danese S; Bonovas S; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biosimilars: opportunities and risks].
    Grieshaber-Bouyer R; Lorenz HM
    Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biologics and biosimilars].
    Guðmundsson K
    Laeknabladid; 2014 May; 100(5):267. PubMed ID: 24846948
    [No Abstract]   [Full Text] [Related]  

  • 38. Biosimilars in IBD: hope or expectation?
    Gecse KB; Khanna R; van den Brink GR; Ponsioen CY; Löwenberg M; Jairath V; Travis SP; Sandborn WJ; Feagan BG; D'Haens GR
    Gut; 2013 Jun; 62(6):803-7. PubMed ID: 23503043
    [No Abstract]   [Full Text] [Related]  

  • 39. Biosimilar therapy for inflammatory bowel disease.
    Avendaño-Solá C; Panés J; Calvo G
    Rev Esp Enferm Dig; 2014 Jan; 106(1):65-6. PubMed ID: 24689722
    [No Abstract]   [Full Text] [Related]  

  • 40. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.